Active Circulating Blood Volume During Hemodialysis: A Bench Model.

Intradialytic hypotension due to excessive fluid removal is a common complication of hemodialysis. A bench model was constructed to evaluate quantification of active circulating blood volume (ACBV). The model included a central pump representing the heart and compartments to represent the central and peripheral circulation. A blood oxygenator was used to simulate lung volume and two containers represented fast and slow circulation compartments. A separate dialysis circuit with a blood pump and two ultrasound flow-dilution probes was incorporated. Vascular access was simulated with both a shunt (fistula or graft) and a central venous catheter. Hypertonic saline (5%) was circulated in the system. A bolus of isotonic saline was introduced in the dialysis circuit, which dispersed through the physiologic model. ACBV was measured by comparing the baseline dilution curve to the curve as it returned to the probes. To evaluate the sensitivity of this technique, we investigated changing cardiac output, central venous volume, shunt flow, vascular access type, and HD pump flow. Overall percentage error (mean ± SD) across all tests (n = 15 conditions, each in triplicate) was 2.6% ± 7.4%. This study demonstrates the ability to accurately measure ACBV on the bench.

New noninvasive methodology to measure cardiac output in veno-venous extracorporeal membrane oxygenation patients.

INTRODUCTION: Cardiac output (CO) measurement is vital in veno-venous extracorporeal membrane oxygenation patient population to evaluate oxygen delivery and to early identify right heart failure. Standard clinical methods like pulmonary artery thermodilution and transpulmonary thermodilution are known to be inaccurate in the veno-venous extracorporeal membrane oxygenation setting, especially at high levels of recirculation. OBJECTIVE: The aim of the study was to develop a simple noninvasive method to measure CO in patients during veno-venous extracorporeal membrane oxygenation. METHODS: A mathematical model was developed where CO was analyzed as a combination of two flows: oxygenated blood from extracorporeal membrane oxygenation and less oxygenated mixed venous blood. The system of two mass balance equations for oxygen saturations was introduced to calculate CO. The procedure included measurement of recirculation (ELSA Monitor Transonic Systems Inc. Ithaca, USA) and arterial saturation at two extracorporeal membrane oxygenation flows after temporary pump flow decrease. Mathematic modeling that utilized a crude Monte Carlo method was used to analyze theoretical errors in CO calculations from unknown behavior of venous saturation. The developed concept was retrospectively applied to clinical data archive of 17 adult patients on veno-venous extracorporeal membrane oxygenation that included 52 measurement sessions. RESULTS: Mathematical modeling suggests that proportion of results with error ⩽10% was between 86% and 100% if pre-oxygenated saturation was available and it was between 78% and 86% if pre-oxygenated saturation was not available. Application of two mass balance equation concept to clinical data suggests that as the decrease of the arterial saturation reaches 6% due to flow decrease, then CO calculations becomes highly reliable as 96% (2 standard deviations) of the results has a reproducibility within 6.4%. CONCLUSION: The mathematical model and clinical retrospective analysis demonstrates that the new methodology has the potential to accurately measure CO in veno-venous extracorporeal membrane oxygenation patients. The next step is validation in animal and clinical settings.

In vitro and in vivo assessment of oxygenator blood volume for the prediction of clot formation in an ECMO circuit (theory and validation).

INTRODUCTION: Clotting is one of the major causes of mortality and morbidity during extracorporeal membrane oxygenation (ECMO). A large meta-analysis study suggests that 29% of patients require the oxygenator to be replaced during ECMO. As clots usually form in the oxygenator, the oxygenator blood volume (OXBV) decreases over time. The currently used pressure gradient as a predicator of clot formation is unreliable. OBJECTIVE: The aim of this study was to develop and validate ultrasound dilution technology in a quantitative assessment of clotting, using measurements of OXBV. METHODS: OXBV was measured using the ELSA monitor (Transonic Systems Inc., Ithaca, NY, USA) from the transit time of a saline bolus passing through the oxygenator as recorded by a sensor placed after the oxygenator. The accuracy and reproducibility (coefficient of variation [CV]) of OXBV measurement and its independence from ECMO flow was assessed in vitro in lambs and from a clinical data archive. RESULTS: The in vitro accuracy compared with volumetric measurements of OXBV of 22-134 ml at flows of 300-700 ml/min was -0.8±6.6%. For an OXBV of 355 ml at flows of 1020-7000 ml/min, accuracy was -0.4±1.6%. In 88 animal OXBV measurements, the CV was 1.49±1.12%. For an OXBV of 153 (range 42-387 ml), clinical measurements at flow ranged from 210-5960 ml/min, with a CV of 3.20±2.44 %. CONCLUSION: Dilution technology has the ability to accurately and reproducibly assess the clotting process in the oxygenator. Larger studies are needed to establish guidelines for the prediction of imminent clotting and may help to avoid unnecessary circuit changes.

Why vascular access trials on flow surveillance failed.

INTRODUCTION: Since the introduction of access flow surveillance technology for routine patient screening in 1995, more than 30 clinical trials have been presented in peer reviewed journals. Despite overall positive outcomes, some trials, including randomized control trials (RCTs), failed to produce positive outcomes for access surveillance. The purpose of this study is to analyze published data related to the main component of access surveillance--adequate increase of access flow after percutaneous transluminal angioplasty (PTA). RESULTS: A total of nine studies for arteriovenous grafts (AVGs) that include 350 accesses and nine studies for arteriovenous fistula (AVF) that included 503 accesses were considered for analysis from 14 publications. Practically, all reference data find high sensitivity (>90%) of access flow measurement to predict 50% stenosis. Mean access flow increase after PTA in AVGs was 319 ml/min (from 238 to 524 ml/min). Mean access flow increase in AVFs was 331 ml/min (from 195 to 402 ml/min). Relative flow increase in AVFs was 1.6 times greater than in AVGs. The authors of failed RCT for AVGs either did not select patients for PTA based on KDOQI guidelines and did not provide/analyze PTA flow results data, or reveal data that obviously show failure of PTA to adequately improve access flow. SUMMARY: Access flow surveillance successfully identifies patients with hemodynamically significant stenosis. PTA performed on AVFs produce better hemodynamic results than in AVGs. Inadequate flow increases during PTA and not following KDOQI guidelines are major contributing factors for failed AVG randomized tails. Radiologists should use objective means for flow evaluation during PTA.

Theory and in vitro validation of a new extracorporeal arteriovenous loop approach for hemodynamic assessment in pediatric and neonatal intensive care unit patients.

OBJECTIVES: No simple method exists for repeatedly measuring cardiac output in intensive care pediatric and neonatal patients. The purpose of this study is to present the theory and examine the in vitro accuracy of a new ultrasound dilution cardiac output measurement technology in which an extracorporeal arteriovenous tubing loop is inserted between existing arterial and venous catheters. DESIGN: Laboratory experiments. SETTING: Research laboratory. SUBJECTS: None. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: In vitro validations of cardiac output, central blood volume, total end-diastolic volume, and active circulation volume were performed in a model mimicking pediatric (children 2-10 kg) and neonatal (0.5-3 kg) flows and volumes against flows and volumes measured volumetrically. Reusable sensors were clamped onto the arterial and venous limbs of the arteriovenous loop. A peristaltic pump was used to circulate liquid at 6-12 mL/min from the artery to the vein through the arteriovenous loop. Body temperature injections of isotonic saline (0.3-10 mL) were performed. In the pediatric setting, the absolute difference between cardiac output measured by dilution and cardiac output measured volumetrically was 3.97% +/- 2.97% (range 212-1200 mL/min); for central blood volume the difference was 4.59% +/- 3.14% (range 59-315 mL); for total end-diastolic volume the difference was 4.10% +/- 3.08% (range 24-211 mL); and for active circulation volume the difference was 3.30% +/- 3.07% (range 247-645 mL). In the neonatal setting the difference for cardiac output was 4.40% +/- 4.09% (range 106-370 mL/min); for central blood volume the difference was 4.90% +/- 3.69% (range 50-62 mL); and for active circulation volume the difference was 5.39% +/- 4.42% (range 104-247 mL). CONCLUSIONS: In vitro validation confirmed the ability of the ultrasound dilution technology to accurately measure small flows and volumes required for hemodynamic assessments in small pediatric and neonatal patients. Clinical studies are in progress to assess the reliability of this technology under different clinical situations.

Determining lung water volume in stable hemodialysis patients.

Lung water (LW) reflects the water content of the lung interstitium. Because hemodialysis patients have expanded total body water (TBW) they may also have increased LW. Hypertonic saline promotes a flux of water from lung to blood, which is measured by ultrasound flow probes on hemodialysis tubing. The volume of flux is an indirect measure of LW. Our purpose was to determine the feasibility and reproducibility of LW derived with ultrasound velocity dilution, to determine the effect of ultrafiltration on LW in stable hemodialysis patients, and to compare changes in LW with fluid compartment shifts using bioimpedance. Lung water, cardiac output, total body water, and extracellular and intracellular fluid volumes were measured in 24 stable hemodialysis patients at the beginning of hemodialysis and after ultrafiltration. The LW values at the beginning of hemodialysis (298.8 +/- 90.2 ml or 3.67 +/- 1.47 ml/kg) fell during hemodialysis (250.8 +/- 55.8 ml or 3.12 +/- 0.96 ml/kg; p < 0.05), as did TBW and extracellular fluid volumes (p < 0.001). Cardiac output, cardiac index, and central blood volume also decreased significantly with ultrafiltration (p < 0.005, p < 0.005, and p < 0.01, respectively). Results showed that stable hemodialysis patients have higher specific LW values (3.67 ml/kg) than the normal population (2 ml/kg) and ultrafiltration produces a significant decline in LW values.

Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms.

High-output cardiac failure can be a rare complication of high-output arteriovenous fistula. The authors present a case in which a hemodialysis patient with a high-flow arteriovenous fistula has cardiac failure that improves with fistula closure. The hemodynamic effects of a fistula are reviewed, and the hemodialysis literature regarding high-output cardiac failure is summarized. To gain insight into the problem of high-output cardiac failure, research efforts should focus on the prospective monitoring of high-access flows.

Access flow measurement during surveillance and percutaneous transluminal angioplasty intervention.

The introduction of routine access flow measurement methodology has enabled accurate identification of problematic accesses and provided a means for follow-up evaluation. These methods have uncovered, in some cases, that interventions are either immediately unsuccessful or that they fail within 3 months to maintain flow above preintervention levels. The purpose of this article is to analyze the main problems that occur at each step in the loop of flow surveillance-intervention-follow-up and to provide suggestions for improving outcomes. Analysis of published access flow data suggests that the main problems lie in the areas of inadequate analysis of flow surveillance data, lack of objective technology for quantifying intervention effectiveness, and lack of follow-up flow measurements in the hemodialysis (HD) unit after the intervention. The following three recommendations may improve surveillance outcomes: 1). using a reliable access flow technology combined with analysis of all hemodynamic data (including mean arterial pressure) before referring patients for angiography to decrease surveillance false positives; 2). performing intra-access blood flow measurement during angioplasty, which may improve outcomes by giving warning of errors before the patient leaves the intervention suite. Success achieved in restoring flow as measured during the intervention usually predicts good immediate outcomes in the HD unit; 3). measuring access flows during the next week after angioplasty. If the results are unsatisfactory, the patient should be further evaluated to avoid a potential thrombotic event.

Relationship between vascular access flow and hemodynamically significant stenoses in arteriovenous grafts.

BACKGROUND: Vascular access dysfunction is a major source of hemodialysis patient morbidity. The NKF K/DOQI Guidelines promote access flow monitoring as the most preferred access surveillance method and have established access flow thresholds for fistulography: an absolute threshold of 600 ml/min and a dynamic threshold of flow less than 1000 ml/min that has decreased by more than 25% over 4 months. The Guidelines apply universally to accesses of different types, sizes, locations, and initial flow rates. METHODS: This article studies the application of access flow guidelines with human experimental data, animal experimental data, and a mathematical model of the arteriovenous graft system. RESULTS AND CONCLUSIONS: Analysis of experimental data and the mathematical model shows that a 20 to 30% and greater decrease in graft flow generally suggests the appearance of hemodynamically significant stenosis as defined by flow criteria. The model suggests that not all 50 to 60% stenoses may be hemodynamically significant or the most flow limiting. The mathematical model also suggests that positive predictive value of access surveillance may be increased for high-flow upper arm grafts by increasing the dynamic K/DOQI threshold from 1000 ml/min to 1200 ml/min.

Use of a catheter-based system to measure blood flow in hemodialysis grafts during angioplasty procedures.

PURPOSE: The goals of this investigation were to evaluate the accuracy and reliability of the Angioflow meter system with use of in vitro and in vivo methods and to compare it to the standard Transonics HD01 system in a clinical setting. MATERIALS AND METHODS: The Angioflow meter system consists of a 6-F endovascular catheter and a laptop computer containing proprietary software for this application. Bench-top testing with use of a flow model was performed to determine the accuracy of the Angioflow meter system. Initial in vivo studies were performed with use of an animal model to assess the endovascular performance of the Angioflow meter system. Subsequently, a human clinical trial was performed to compare the Angioflow meter to the standard Transonics HD01 system. Twenty-five patients with dysfunctional (<600 mL/min) hemodialysis grafts were referred for fistulography and angioplasty. Intragraft blood flow measurements were obtained before and after angioplasty with use of both the Angioflow meter system and the Transonics HD01 system. A comparison of the two systems was performed. RESULTS: Bench-top testing and animal studies demonstrated an excellent (r =.98) correlation between the measurements of the Angioflow meter and volumetric flow measurements. In the clinical trial, there was reasonable correlation (r =.72) between the blood flow measurements obtained with use of the Angioflow meter and Transonics HD01 system. The reproducibility of consecutive measurements with the Angioflow meter was excellent (r =.98). The mean increase in intragraft blood flow after angioplasty was 320 mL/min. CONCLUSION: The Angioflow meter is an accurate and reliable endovascular device for measuring intragraft blood flow during interventional procedures. Use of this catheter-based system should prove beneficial for quantifying the success of endovascular interventions, the assessment of arterial inflow, and identification of inconspicuous lesions.